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Abstract
Background—Probe-based confocal laser endomicroscopy (pCLE) allows real-time detection of
neoplastic Barrett’s esophagus (BE) tissue. However, the accuracy of pCLE in real time has not
yet been extensively evaluated.
Objective—To compare the sensitivity and specificity of pCLE in addition to high-definition
white-light endoscopy (HD-WLE) with HD-WLE alone for the detection of high-grade dysplasia
(HGD) and early carcinoma (EC) in BE.
Design—International, prospective, multicenter, randomized, controlled trial.
Setting—Five tertiary referral centers.
Patients—A total of 101 consecutive BE patients presenting for surveillance or endoscopic
treatment of HGD/EC.
Interventions—All patients were examined by HD-WLE, narrow-band imaging (NBI), and
pCLE, and the findings were recorded before biopsy samples were obtained. The order of HD-
WLE and NBI was randomized and performed by 2 independent, blinded endoscopists. All
suspicious lesions on HD-WLE or NBI and 4-quadrant random locations were documented. These
locations were examined by pCLE, and a presumptive diagnosis of benign or neoplastic (HGD/
EC) tissue was made in real time. Finally, biopsies were taken from all locations and were
reviewed by a central pathologist, blinded to endoscopic and pCLE data.
Main Outcome Measurements—Diagnostic characteristics of pCLE.
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tResults—The sensitivity and specificity for HD-WLE were 34.2% and 92.7%, respectively,
compared with 68.3% and 87.8%, respectively, for HD-WLE or pCLE (P = .002 and P < .001,
respectively). The sensitivity and specificity for HD-WLE or NBI were 45.0% and 88.2%,
respectively, compared with 75.8% and 84.2%, respectively, for HD-WLE, NBI, or pCLE (P = .01
and P = .02, respectively). Use of pCLE in conjunction with HD-WLE and NBI enabled the
identification of 2 and 1 additional HGD/EC patients compared with HD-WLE and HD-WLE or
NBI, respectively, resulting in detection of all HGD/EC patients, although not statistically
significant.
Limitations—Academic centers with enriched population.
Conclusions—pCLE combined with HD-WLE significantly improved the ability to detect
neoplasia in BE patients compared with HD-WLE. This may allow better informed decisions to be
made for the management and subsequent treatment of BE patients.
Barrett’s esophagus (BE) is the premalignant lesion for adenocarcinoma of the esophagus
and gastroesophageal junction.1 It is a condition in which the squamous mucosa of the distal
esophagus is replaced by columnar mucosa, specifically, intestinal metaplasia. The current
standard of endoscopy with biopsies has several limitations, including sampling error and
inconsistent histopathological interpretation. Moreover, dysplastic epithelium is often
inconspicuous, patchy, and macroscopically indistinguishable from metaplastic tissue. New
endoscopic imaging techniques to improve the accuracy of endoscopic diagnosis have been
developed, with various degrees of evaluation already performed.2–7 These optical-based
techniques, such as high-definition white-light endoscopy (HD-WLE), narrow-band imaging
(NBI), and confocal laser endomicroscopy (CLE), can generally be categorized as broad-
field (red-flag techniques) and focal imaging techniques. The broad-field techniques are
good for providing an overview of the entire BE segment, whereas focal techniques can
provide greater detail of the area of interest.
WLE has improved considerably with the availability of high-definition video endoscopes.
This allows more detailed examination of the mucosal, glandular, and vascular structures.2,3
NBI is a technique that increases the mucosal contrast without the use of dyes, based on
differential light penetration in the tissue, depending on its wavelength, and can be used as a
broad-field evaluation technique.4 Probe-based CLE (pCLE) is a focal technique that
provides dynamic microscopic views of the mucosa in real-time during an ongoing
procedure.8–10 This development has improved the visualization of the subtle BE lesions to
a point where we can see the cellular details in vivo during endoscopy, allowing a diagnosis
to be made in the GI endoscopy unit. However, the comparative sensitivities of these
enhanced endoscopic techniques are not known.
STUDY AIMS
The primary aim was to evaluate the per-location sensitivity and specificity of pCLE in
addition to HD-WLE compared with HD-WLE alone for the detection of high-grade
dysplasia (HGD) and early carcinoma (EC) in BE patients.
Secondary aims included the evaluation of per-location sensitivity and specificity of each
individual imaging modality (HD-WLE, NBI, pCLE); per-location sensitivity and specificity
of pCLE in addition to HD-WLE or NBI (HD-WLE or NBI or pCLE); and activity-specific
procedure time, total procedure time, procedure complexity, and potential training effect.
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Study subjects
The study protocol was approved by the institutional review board of all participating
institutions and conducted according to the Declaration of Helsinki. All patients provided
written, informed consent.
Consecutive patients undergoing BE surveillance and/or referred for BE-associated
neoplasia (HGD/EC) evaluation and treatment were prospectively enrolled in this trial at 5
hospitals (Mayo Clinic, Jacksonville, Fla; Columbia University Medical Center, New York,
NY; Veterans Affairs Hospital, Kansas City, Mo; Centre Hospitalier Universitaire, Nantes,
France; Klinikum rechts der Isar, Munich, Germany). All patients enrolled in the study
received proton-pump inhibitor treatment for at least 2 weeks before enrollment. Patients
with erosive esophagitis, inability to obtain biopsy samples because of anticoagulation,
varices, known allergy to sodium fluorescein, pregnancy, presence of an esophageal mass or
nodule greater than 10 mm, and renal insufficiency were excluded from the trial.
Pre-enrollment training
Of the 11 investigators who performed pCLE procedures during the study, only 4 had
previous experience with pCLE. Before enrolling the first patient, each endoscopist
completed a standard training module consisting of NBI and pCLE videos and still images.
The criteria used for interpreting pCLE videos were described previously.9 Each endoscopist
completed a review of 20 unknown video cases and had to repeat the test until a minimum
score of 90% correct diagnoses was reached before being allowed to enroll patients.
Study design
Although not necessary for the primary aim of the study, a randomization was performed
between the HD-WLE and NBI endoscopic procedures to evaluate the individual diagnostic
performances and contribution of each imaging modality (Fig. 1). A tandem design was
adopted in which each location/patient acted as its/his or her own control. All patients
underwent examination of their BE segment by 3 imaging modalities: HD-WLE, NBI, and
pCLE (procedures 1, 2, and 3). The order of procedures 1 and 2 was randomized before
pCLE imaging and tissue sampling. Every attempt was made to blind the endoscopist to
each patient’s history and previous endoscopic findings.
Patients were randomly allocated to the 2 endoscopy sequences (HD-WLE followed by NBI,
NBI followed by HD-WLE) via regulatory-compliant electronic data capture software
(VISION-EDC system; Prelude Dynamics, Austin, Tex). Patients were randomized in a 1:1
ratio in blocks of 2 stratified by study site and procedure indication (BE surveillance or BE
treatment). The electronic data capture system was used to collect data starting with patient
screening and eligibility check and to randomize patients.
Endoscopic procedures
Procedure 1: HD-WLE—All patients underwent standard HD-WLE examination using an
Olympus 180 HD endoscope (Olympus Inc, Center Valley, Pa) in white-light mode (using a
4-mm clear cap distal attachment without magnification). The BE length was measured from
the gastroesophageal junction to the proximally displaced squamocolumnar junction and
recorded using the Prague C & M criteria.11 If visible lesions were identified (suspicious for
neoplasia), they were graded using the Paris classification system and their distance and
clock position (eg, 38 cm, 8 o’clock) were recorded.12 Biopsy samples were not obtained
until after all procedures (1, 2, and 3) were complete.
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same Olympus 180 HD endoscope in the NBI mode (using a 4-mm clear cap distal
attachment without magnification). In addition to the recording of all visible lesions by NBI
(as described for procedure 1), any abnormal mucosal and/or vascular patterns seen with
NBI were also identified as suspicious locations.6
Unblinding and location matching: After procedures 1 and 2 were complete and all
suspicious locations documented by each technique had been noted, the individual results of
the first and second procedures were unblinded. Locations were paired carefully (if
applicable) during the unblinding step. Any suspicious location that remained unclear was
resolved by review of the photographs (by each procedure) by both endoscopists to match
each site.
Procedure 3: pCLE—pCLE examination was performed using a confocal miniprobe
(GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France), which has a field of
view of 240 µm, a lateral resolution of 1 µm, and an imaging depth of 60 µm below the
tissue surface. A previously published methodology was used to precisely match the pCLE
examination and the biopsy sampling.9 The immediate vicinity of each location was
“marked” using spot coagulation with argon plasma coagulation (ERBE, Tübingen,
Germany). Suspicious (targeted) locations were marked first, followed by nontargeted (NBI
and HD-WLE) normal random sites. After injection of sodium fluorescein (2.5 mL, 10%),
the pCLE miniprobe was passed through the endoscope accessory channel and placed in
gentle contact with the BE surface. pCLE imaging was performed at all suspicious
(observed by either WLE or NBI) and random locations (ie, 4 quadrants every 2 cm per the
Seattle surveillance protocol). The investigator made a presumptive diagnosis of dysplastic
(HGD/EC) or nondysplastic at each site examined by pCLE before biopsy samples were
obtained.
Additional data collection: The total time required for each procedure was recorded from
endoscope insertion to removal. The time was divided into HD-WLE inspection, NBI
inspection, argon plasma coagulation marking, pCLE inspection, and biopsy time. Procedure
complexity was also captured prospectively during the study by grading on a 5-point Likert
scale from 1 (easy) to 5 (difficult), including the ease of performing pCLE, ease of
interpreting pCLE images, and ease of performing biopsies.
Histopathological assessment
Each biopsy sample was placed in a separate jar and analyzed individually. Alternatively,
when placed in the same jar, the 4 biopsy samples (from 1 level, eg, 38 cm) were stained
with 4 different inks representing a different quadrant (and documented). All deidentified
slides were sent for central pathology and read by a single blinded expert GI pathologist.
Each biopsy was classified as squamous epithelium, gastric metaplasia, intestinal metaplasia
without dysplasia, low-grade dysplasia (LGD), HGD, or EC according to published
standards.13
Data collection, analysis, and sample size
The proportions of lesions classified as suspicious or nonsuspicious by HD-WLE, NBI, and
pCLE were tabulated by the presence and absence of disease (ie, HGD/EC) based on
histological diagnosis (criterion standard). Estimates and 95% confidence intervals were
calculated for the primary aims. Statistical significance calculations (P values) were
performed for individual procedures (HDWLE, NBI, pCLE) and their combinations using
repeated-measures log-linear models. Calculations for procedure times were also performed
with analyses of covariance (including maximum BE extent) on within-subject differences
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tof completion times. HD-WLE, NBI, pCLE, and biopsies were compared with regard to the
mean time to completion using a repeated-measures linear model with pairwise contrasts
corrected for multiple comparisons using the Tukey method. All statistical testing was 2
sided at a significance level of 5% using SAS version 9.2 for Windows (SAS Institute, Cary,
NC).
Based on published literature, a numerical simulation was performed assuming that HD-
WLE sensitivity was 79% and specificity was 75%.14 Power calculations indicated that,
with these assumptions, the study would attain a power of 80% with 100 subjects and 10
locations per subject if the sensitivity and specificity of pCLE in addition to HD-WLE were
both equal to 90%.
RESULTS
Patient characteristics
Between November 2008 and September 2009, 122 consecutive BE patients were
prospectively enrolled at the 5 participating centers by the investigators at each site. Of the
enrolled patients, 21 were excluded from the analysis (Fig. 1). The mean age of the patients
was 65.1 years (range 27–90 years), and 14% were women (Table 1). The mean (standard
deviation) Prague C & M extents were 1.91 (2.95) and 3.61 (3.24) cm, respectively. Fifty-
seven patients were referred for routine BE surveillance, whereas 44 were referred for
management of a history of HGD/EC.
From the enrolled patients, a total of 955 locations (from 122 patients) were identified, of
which 874 were available for final analysis. Locations were excluded from the analysis for
patients withdrawn or screen failures (25 locations), absence of central pathology reading
because of insufficient tissue/lost slides (35 locations), or if EMR samples rather than
forceps biopsy samples were obtained (21 locations).
Neoplasia distribution in study population
Using the worst location diagnosis (from any of the targeted or 4-quadrant random biopsies)
to define the patient’s disease status, of the 101 patients, 66 (65%) had no dysplasia
(intestinal metaplasia only), 4 (4%) had LGD, 6 (6%) had HGD, and 25 (25%) had EC. Of
the 31 patients with HGD/EC, 27 had endoscopically visible small lesions on examination
with HD-WLE. Four were referred for routine BE surveillance and 27 for known HGD/EC.
On a per-location distribution, 143 locations were suspicious on HD-WLE or NBI and 731
were true random locations. A total of 728 locations (83%) had no dysplasia, 26 (3%) had
LGD, 60 (7%) had HGD, and 60 (7%) had cancer.
Primary endpoint: per-location analysis on sensitivity and specificity of HD-WLE versus
HD-WLE or pCLE
A location was ruled as positive on biopsy if pathology interpretation was HGD/EC; positive
on pCLE if HGD/EC was suspected based on pCLE images (Fig. 2); and positive on HD-
WLE/NBI if a suspicious location was identified by the investigator. Combining modalities
meant that a location was considered positive if at least 1 modality was positive. All random
4-quadrant locations were considered negative on HD-WLE and NBI.
Table 2 displays the results for the primary outcomes using these definitions. The sensitivity
and specificity for HD-WLE were 34.2% and 92.7%, respectively, compared with 68.3%
and 87.8%, respectively, for HD-WLE or pCLE (P = .002 and P < .001, respectively). This
translated into 41 additional locations with HGD/EC being identified when pCLE was used
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tin conjunction with HD-WLE compared with HD-WLE alone. The relative sensitivity
(using 95% CI) between HD-WLE and HD-WLE or pCLE was 2.0 (P = .002).
Secondary endpoints: per-location accuracy analyses
Table 3 displays the results of the per-location analyses for each imaging modality along
with various combinations. NBI alone had a higher sensitivity than HD-WLE alone, but this
was not statistically significant (P = .29). pCLE alone was more sensitive than HD-WLE
alone (P = .02) and NBI alone (P = .13), while having no difference in specificity. When
areas that appeared abnormal (ie, visible lesions) during HD-WLE examination were
excluded, the sensitivity and specificity of pCLE alone were 51.9% and 94.7%, respectively,
resulting in detection of 41 additional areas of HGD/EC. When areas that appeared
abnormal (ie, visible lesions) during HD-WLE or NBI examination were excluded, the
sensitivity and specificity of pCLE alone were 56.1% and 95.5%, respectively, resulting in
detection of 37 additional areas of HGD/EC.
The addition of NBI to HD-WLE did not result in any statistically significant differences in
sensitivity (P = .11), but was less specific (P < .01). Compared with HD-WLE or NBI, HD-
WLE or pCLE had higher sensitivity (P < .001) but similar specificity (P = .87). HD-WLE
or NBI or pCLE was more sensitive (P = .01) and less specific (P = .02) compared with HD-
WLE or NBI, and it had similar sensitivity (P = .25) and specificity (P = .05) compared with
HD-WLE or pCLE. The combination of HD-WLE or NBI or pCLE had the highest
sensitivity with 37 additional HGD/EC locations identified compared with HD-WLE or NBI
alone.
Secondary endpoints: per-patient accuracy analysis
Thirty-one patients were diagnosed with HGD/EC as the worst diagnosis with any 1 of the
locations being read as such by central pathology (Table 4). The use of pCLE in conjunction
with HD-WLE and HD-WLE or NBI resulted in identifying 2 and 1 additional HGD/EC
patients compared with HD-WLE and HD-WLE or NBI, respectively, resulting in the
detection of all HGD/EC patients in the second case (100% sensitivity for HD-WLE or NBI
or pCLE). However, there were no statistically significant differences in sensitivity between
any of the imaging strategies.
Secondary endpoints: procedure time, complexity, and training effect
The mean total procedure time was 30 minutes 7 seconds, and the mean time needed to
perform pCLE examination was 9 minutes 8 seconds. To assess the presence of a potential
training effect, procedure durations for the initial half of enrolled patients (n = 44) were
compared with those of the second half of patients (n = 45) at the 3 clinical sites that
enrolled more than 20 patients. There were no significant differences with regard to the
mean duration of pCLE, HD-WLE, or NBI. There were also no significant differences
between the BE extents: (C [cm]) (first half, 1.9 ± 2.8; second half, 1.5 ± 2.6; P = .52) or (M
[cm]) (first half, 3.7 ± 3.7; second half, 3.2 ± 2.7; P = .48) among the enrolled patients.
With restriction to the 3 centers that enrolled more than 10 subjects, the percentages of
subjects who scored 1 or 2 with regard to the ease of performing pCLE (79.3%), interpreting
pCLE images (77%), and performing biopsies (81.6%) were not significantly different from
each other (performing pCLE vs biopsy, P = .70; interpreting pCLE images vs biopsy, P = .
45; performing pCLE vs interpreting pCLE images, P = .71).
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Based on the study data, if targeted and random 4-quadrant biopsies were only performed in
patients with suspicious lesions (visualized either by HD-WLE, NBI, or pCLE), 39% of
patients could forego biopsies, and none of the patients with HGD/EC would be missed.
DISCUSSION
Guidelines recommend that patients with BE undergo surveillance endoscopy with the goal
of detecting dysplasia and early esophageal adenocarcinoma.15,16 HD-WLE has markedly
improved the endoscopy image quality and is now widely used for surveillance endoscopy.
NBI, a method of electronic chromoendoscopy, has been shown to be superior to WLE in
detecting significantly more patients with dysplasia.17 This maintains the need to rely on
subsequent histopathological assessment and interpretation for patient management.
pCLE is an in vivo imaging tool that has the ability to display real-time histology to the
endoscopist.8–10 Previous studies (nonrandomized, controlled trials) have shown a high
sensitivity and specificity of pCLE in diagnosing HGD/cancer in BE patients. In a pilot
study, Pohl et al9 evaluated the preliminary accuracy of pCLE for HGD and EC in BE
patients. They evaluated 296 biopsy sites from 38 patients with a median BE length of 3 cm.
The overall accuracy of pCLE was 88% to 93%, with sensitivity of 75% to 80%, and
specificity of 89% to 94%, a positive predictive value of 44.4%, and a negative predictive
value (NPV) of 98.8%. Likewise, Kiesslich et al,18 using an integrated endoscope–based
CLE system (joint venture between Pentax, Tokyo, Japan, and Optiscan Pty Ltd, Melbourne,
Australia), were able to achieve a high accuracy both in the diagnosis of BE metaplasia and
neoplasia (96.8% and 97.4%, respectively). The interobserver agreement using pCLE was
assessed prospectively in a study by Wallace et al,19 which constituted the training phase of
the current study. There was good overall agreement on the pCLE diagnosis (κ = 0.72 [95%
CI, 0.58–0.86]); endoscopists with previous pCLE experience had a much higher agreement
(κ = 0.83 [95% CI, 0.64–1.0]). These results suggest that pCLE for the diagnosis of
neoplasia in BE has high accuracy and reliability with a short associated learning curve.
Finally, using an endoscope-based CLE system, Dunbar et al20 also demonstrated an
increased yield of neoplasia compared with a 4-quadrant biopsy protocol. Although the
sensitivity of pCLE found in this study was lower than that found in some of the previous
studies, this study used real-time prediction of histology, had 11 endoscopists from multiple
centers, and used different criteria to interpret pCLE results, which may have contributed to
the variable results.18
To our knowledge, this is the first international, multi-center, prospective, randomized,
controlled trial that has demonstrated significantly improved sensitivity in detecting HGD/
EC using pCLE. pCLE had per-location sensitivity and specificity of 62.5% and 92.7%,
respectively, compared with 34.2% and 92.7%, respectively, for HD-WLE, the primary aim
of the study. This resulted in a twofold increase in sensitivity for the detection of HGD/EC
(from 34.2% to 68.3%), although with a minimal decrease in specificity (from 92.7% to
87.8%) when pCLE was used in combination with HD-WLE compared with HD-WLE
alone. Overall, the combination of pCLE with HD-WLE led to the recognition of 41
additional locations with HGD/EC compared with HD-WLE alone. There was no
statistically significant learning curve when the early patients (initial 50%) were compared
with the late patients (last 50%). Furthermore, the ease of pCLE use and image
interpretation was not considered more difficult by the endoscopist than that of obtaining a
biopsy sample.
There are several potential clinical implications of pCLE use in the BE clinical setting. The
improved sensitivity with the detection of additional neoplastic areas has a significant
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timpact on the clinical management in the era of endoscopic treatment of HGD/EC. If
additional areas within a BE segment with HGD/EC were identified, the endoscopist may
change the course of treatment with more widespread mucosal resection and/or submucosal
dissection. Thus, a case can be made for real-time decision making and possible treatment
with EMR or ablative therapies in selected patients after diagnosing HGD/EC using pCLE.
On the other hand, a high NPV offers a higher degree of confidence in confirming the
absence of HGD/EC and is highly desirable for a better informed decision as to where tissue
should be sampled. In this prospective study, we were able to show that the NPV of pCLE
used in combination with HD-WLE was 91% and was 95.6% when combined with both
HD-WLE and NBI. This can, in turn, translate into a high degree of confidence in ruling out
dysplasia during surveillance endoscopy.
There are several limitations to our study. Our study was performed at expert academic
centers by endoscopists experienced in BE and pCLE. The study cohort is not representative
of the general population, thereby limiting its generalizability. This also caused an
artificially enriched population of patients with neoplasia. In such a population with
artificially enriched HGD and EC, a lower NPV would be expected than in a traditional
surveillance population. However, we found a high NPV when pCLE was used in
combination with HD-WLE (and NBI). Another limitation is the inherent sampling error
when performing focal examination: it is possible that pCLE images/videos did not correlate
with the sites from which the biopsy samples were obtained. This risk was mitigated in our
study design by the fact that all locations were marked with argon plasma coagulation in
their direct vicinity to ensure the best possible correlation of biopsy- and pCLE-examined
locations. The study was powered to find a difference in ability to detect locations with
HGD/EC rather than patients with HGD/EC. Although HD-WLE or NBI had a higher
sensitivity for patients with HGD/EC compared with HD-WLE or pCLE, there were no
statistically significant differences in sensitivity between any of the imaging strategies.
Consequently, it remains uncertain which imaging strategy (if any) is superior for detection
of HGD/EC from a patient-based perspective. In addition, we relied on the yield of biopsy
samples of suspicious lesions plus 4-quadrant random locations to determine the presence/
absence of HGD/EC for each individual patient, which may have underdiagnosed HGD/EC
in the study population. Finally, the cost-effectiveness of pCLE was not evaluated, and, as
such, formal cost-effectiveness analyses are needed.
In conclusion, this study showed that the use of pCLE significantly improved the ability to
detect neoplasia in BE patients. pCLE was easy to use, images were easy to interpret, and
the learning curve was short. This technology may make surveillance endoscopy in BE more
efficient and lead to better informed patient management in real time for immediate
endoscopic treatment.
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• Probe-based confocal laser endomicroscopy is an endoscopic imaging
technology that significantly improves the ability to detect neoplasia in Barrett’s
esophagus (BE) patients while being easy to use and having a short learning
curve.
• The use of this technology may make surveillance endoscopy in BE more
efficient and may lead to better informed patient management in real time for
immediate endoscopic treatment.
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Study design and flow chart. BE, Barrett’s esophagus; HD-WLE, high-definition white-light
endoscopy; NBI, narrow-band imaging; pCLE, probe-based confocal laser endomicroscopy.
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Probe-based confocal laser endomicroscopy images showing nondysplastic Barrett’s
esophagus (BE) (A) and BE with early esophageal adenocarcinoma (B).
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TABLE 1
Patient demographics and study population
Demographics Patients (N = 101)
Age, y (range) 65.1 (27–90)
Male sex, no. (%) 86 (86)
Prague C & M, mean (SD)
  C 1.91 (2.95)
  M 3.61 (3.24)
Histopathology
  No dysplasia 66
  LGD 4
  HGD 6
  Cancer 25
SD, Standard deviation; LGD, low-grade dysplasia; HGD, high-grade dysplasia.
Gastrointest Endosc. Author manuscript; available in PMC 2013 April 18.N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
Sharma et al. Page 15
T
A
B
L
E
 
2
R
e
s
u
l
t
s
:
 
p
e
r
-
l
o
c
a
t
i
o
n
 
a
n
a
l
y
s
i
s
 
o
f
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
d
 
s
p
e
c
i
f
i
c
i
t
y
 
o
f
 
H
D
-
W
L
E
 
v
e
r
s
u
s
 
H
D
-
W
L
E
 
o
r
 
p
C
L
E
S
e
n
s
i
t
i
v
i
t
y
*
(
9
5
%
 
C
I
)
,
%
S
p
e
c
i
f
i
c
i
t
y
*
(
9
5
%
 
C
I
)
,
%
P
P
V
*
 
(
9
5
%
 
C
I
)
,
%
N
P
V
*
 
(
9
5
%
 
C
I
)
,
%
A
r
e
a
s
 
w
i
t
h
 
H
G
D
/
E
C
 
m
i
s
s
e
d
(
t
o
t
a
l
 
H
G
D
/
E
C
 
=
 
1
2
0
)
,
 
n
o
.
 
(
%
)
H
D
-
W
L
E
 
a
l
o
n
e
3
4
.
2
 
(
2
5
.
7
–
4
2
.
7
)
9
2
.
7
 
(
9
0
.
8
–
9
4
.
6
)
4
2
.
7
 
(
3
2
.
8
–
5
2
.
6
)
8
9
.
8
 
(
8
7
.
7
–
9
2
.
0
)
7
9
 
(
6
6
)
H
D
-
W
L
E
 
o
r
 
p
C
L
E
6
8
.
3
 
(
6
0
.
0
–
7
6
.
7
)
8
7
.
8
 
(
8
5
.
5
–
9
0
.
1
)
4
7
.
1
 
(
3
9
.
7
–
5
4
.
5
)
9
4
.
6
 
(
9
2
.
9
–
9
6
.
2
)
3
8
 
(
3
2
)
H D - W L E
,
 
H
i
g
h
-
d
e
f
i
n
i
t
i
o
n
 
w
h
i
t
e
-
l
i
g
h
t
 
e
n
d
o
s
c
o
p
y
;
  p C L E
,
 
p
r
o
b
e
-
b
a
s
e
d
 
c
o
n
f
o
c
a
l
 
l
a
s
e
r
 
e
n
d
o
m
i
c
r
o
s
c
o
p
y
;
  C I
,
 
c
o
n
f
i
d
e
n
c
e
 
i
n
t
e
r
v
a
l
;
  P P V
,
 
p
o
s
i
t
i
v
e
 
p
r
e
d
i
c
t
i
v
e
 
v
a
l
u
e
;
  N P V
,
 
n
e
g
a
t
i
v
e
 
p
r
e
d
i
c
t
i
v
e
 
v
a
l
u
e
;
  H G D / E C
,
h
i
g
h
-
g
r
a
d
e
 
d
y
s
p
l
a
s
i
a
/
e
a
r
l
y
 
c
a
r
c
i
n
o
m
a
.
*
S
e
n
s
i
t
i
v
i
t
y
,
 
s
p
e
c
i
f
i
c
i
t
y
,
 
P
P
V
,
 
a
n
d
 
N
P
V
 
c
a
l
c
u
l
a
t
e
d
 
f
o
r
 
t
h
e
 
d
e
t
e
c
t
i
o
n
 
o
f
 
l
o
c
a
t
i
o
n
s
 
w
i
t
h
 
H
G
D
/
E
C
.
Gastrointest Endosc. Author manuscript; available in PMC 2013 April 18.N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
Sharma et al. Page 16
T
A
B
L
E
 
3
R
e
s
u
l
t
s
:
 
p
e
r
-
l
o
c
a
t
i
o
n
 
a
n
a
l
y
s
i
s
 
o
n
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
d
 
s
p
e
c
i
f
i
c
i
t
y
 
o
f
 
H
D
-
W
L
E
,
 
N
B
I
,
 
p
C
L
E
,
 
a
n
d
 
t
h
e
i
r
 
c
o
m
b
i
n
a
t
i
o
n
s
S
e
n
s
i
t
i
v
i
t
y
*
(
9
5
%
 
C
I
)
,
%
S
p
e
c
i
f
i
c
i
t
y
*
(
9
5
%
 
C
I
)
P
P
V
*
 
(
9
5
%
 
C
I
)
N
P
V
*
 
(
9
5
%
 
C
I
)
,
%
A
r
e
a
s
 
w
i
t
h
 
H
G
D
/
E
C
 
m
i
s
s
e
d
(
t
o
t
a
l
 
H
G
D
/
E
C
 
a
r
e
a
s
 
=
 
1
2
0
)
,
 
n
o
.
 
(
%
)
H
D
-
W
L
E
 
a
l
o
n
e
3
4
.
2
 
(
2
5
.
7
–
4
2
.
7
)
9
2
.
7
 
(
9
0
.
8
–
9
4
.
6
)
4
2
.
7
 
(
3
2
.
8
–
5
2
.
6
)
8
9
.
8
 
(
8
7
.
7
–
9
2
.
0
)
7
9
 
(
6
6
)
N
B
I
 
a
l
o
n
e
4
1
.
7
 
(
3
2
.
8
–
5
0
.
5
)
9
0
.
5
 
(
8
8
.
4
–
9
2
.
5
)
4
1
 
(
3
2
.
3
–
4
9
.
7
)
9
0
.
7
 
(
8
8
.
6
–
9
2
.
8
)
7
0
 
(
5
8
)
p
C
L
E
 
a
l
o
n
e
6
2
.
5
 
(
5
3
.
8
–
7
1
.
2
)
9
2
.
7
 
(
9
0
.
8
–
9
4
.
6
)
5
7
.
7
 
(
4
9
.
2
–
6
6
.
2
)
9
4
.
0
 
(
9
2
.
2
–
9
5
.
7
)
4
5
 
(
3
8
)
H
D
-
W
L
E
 
o
r
 
N
B
I
4
5
.
0
 
(
3
6
.
1
–
5
3
.
9
)
8
8
.
2
 
(
8
5
.
9
–
9
0
.
5
)
3
7
.
8
 
(
2
9
.
8
–
4
5
.
7
)
9
1
.
0
 
(
8
8
.
9
–
9
3
.
0
)
6
6
 
(
5
5
)
H
D
-
W
L
E
 
o
r
 
p
C
L
E
6
8
.
3
 
(
6
0
.
0
–
7
6
.
7
)
8
7
.
8
 
(
8
5
.
5
–
9
0
.
1
)
4
7
.
1
 
(
3
9
.
7
–
5
4
.
5
)
9
4
.
6
 
(
9
2
.
9
–
9
6
.
2
)
3
8
 
(
3
2
)
H
D
-
W
L
E
 
o
r
 
N
B
I
 
o
r
 
p
C
L
E
7
5
.
8
 
(
6
8
.
2
–
8
3
.
5
)
8
4
.
2
 
(
8
1
.
6
–
8
6
.
8
)
4
3
.
3
 
(
3
6
.
6
–
5
0
.
0
)
9
5
.
6
 
(
9
4
.
1
–
9
7
.
2
)
2
9
 
(
2
4
)
H D - W L E
,
 
H
i
g
h
-
d
e
f
i
n
i
t
i
o
n
 
w
h
i
t
e
-
l
i
g
h
t
 
e
n
d
o
s
c
o
p
y
;
  N B I
,
 
n
a
r
r
o
w
-
b
a
n
d
 
i
m
a
g
i
n
g
;
  p C L E
,
 
p
r
o
b
e
-
b
a
s
e
d
 
c
o
n
f
o
c
a
l
 
l
a
s
e
r
 
e
n
d
o
m
i
c
r
o
s
c
o
p
y
;
  C I
,
 
c
o
n
f
i
d
e
n
c
e
 
i
n
t
e
r
v
a
l
;
  P P V
,
 
p
o
s
i
t
i
v
e
 
p
r
e
d
i
c
t
i
v
e
 
v
a
l
u
e
;
  N P V
,
 
n
e
g
a
t
i
v
e
p
r
e
d
i
c
t
i
v
e
 
v
a
l
u
e
;
  H G D / E C
,
 
h
i
g
h
-
g
r
a
d
e
 
d
y
s
p
l
a
s
i
a
/
e
a
r
l
y
 
c
a
r
c
i
n
o
m
a
.
*
S
e
n
s
i
t
i
v
i
t
y
,
 
s
p
e
c
i
f
i
c
i
t
y
,
 
P
P
V
,
 
a
n
d
 
N
P
V
 
c
a
l
c
u
l
a
t
e
d
 
f
o
r
 
t
h
e
 
d
e
t
e
c
t
i
o
n
 
o
f
 
l
o
c
a
t
i
o
n
s
 
w
i
t
h
 
H
G
D
/
E
C
.
Gastrointest Endosc. Author manuscript; available in PMC 2013 April 18.N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
Sharma et al. Page 17
T
A
B
L
E
 
4
R
e
s
u
l
t
s
:
 
p
e
r
-
p
a
t
i
e
n
t
 
a
n
a
l
y
s
i
s
 
o
n
 
s
e
n
s
i
t
i
v
i
t
y
 
a
n
d
 
s
p
e
c
i
f
i
c
i
t
y
 
o
f
 
H
D
-
W
L
E
,
 
N
B
I
,
 
p
C
L
E
,
 
a
n
d
 
t
h
e
i
r
 
c
o
m
b
i
n
a
t
i
o
n
s
D
e
t
e
c
t
i
o
n
 
o
f
H
G
D
/
E
C
S
e
n
s
i
t
i
v
i
t
y
*
(
9
5
%
 
C
I
)
,
%
S
p
e
c
i
f
i
c
i
t
y
*
(
9
5
%
 
C
I
)
,
%
P
P
V
*
 
(
9
5
%
 
C
I
)
,
%
N
P
V
*
 
(
9
5
%
C
I
)
,
%
P
a
t
i
e
n
t
s
 
w
i
t
h
 
H
G
D
/
E
C
 
m
i
s
s
e
d
(
t
o
t
a
l
 
H
G
D
/
E
C
 
=
 
3
1
)
,
 
n
o
.
 
(
%
)
H
D
-
W
L
E
 
a
l
o
n
e
8
7
.
1
0
 
(
7
5
.
3
–
8
.
9
)
7
1
.
4
0
 
(
6
0
.
8
–
8
2
.
0
)
5
7
.
4
0
 
(
4
3
.
3
–
7
1
.
6
)
9
2
.
6
0
 
(
8
5
.
6
–
9
9
.
6
)
4
 
(
1
3
)
H
D
-
W
L
E
 
o
r
 
p
C
L
E
9
3
.
5
0
 
(
8
4
.
9
–
1
0
0
)
6
7
.
1
0
 
(
5
6
.
1
–
7
8
.
1
)
5
5
.
8
0
 
(
4
2
.
3
–
6
9
.
3
)
9
5
.
9
0
 
(
9
0
.
4
–
1
0
0
)
2
 
(
6
)
H
D
-
W
L
E
 
o
r
 
N
B
I
9
6
.
8
0
 
(
9
0
.
6
–
1
0
0
)
5
5
.
7
0
 
(
4
4
.
1
–
6
7
.
4
)
4
9
.
2
0
 
(
3
6
.
6
–
6
1
.
7
)
9
7
.
5
0
 
(
9
2
.
7
–
1
0
0
)
1
 
(
3
)
H
D
-
W
L
E
 
o
r
 
N
B
I
 
o
r
 
p
C
L
E
1
0
0
 
(
1
0
0
–
1
0
0
)
5
5
.
7
0
 
(
4
4
.
1
–
6
7
.
4
)
5
0
 
(
3
7
.
6
–
6
2
.
4
)
1
0
0
 
(
1
0
0
–
1
0
0
)
0
 
(
0
)
H D - W L E
,
 
H
i
g
h
-
d
e
f
i
n
i
t
i
o
n
 
w
h
i
t
e
-
l
i
g
h
t
 
e
n
d
o
s
c
o
p
y
;
  N B I
,
 
n
a
r
r
o
w
-
b
a
n
d
 
i
m
a
g
i
n
g
;
  p C L E
,
 
p
r
o
b
e
-
b
a
s
e
d
 
c
o
n
f
o
c
a
l
 
l
a
s
e
r
 
e
n
d
o
m
i
c
r
o
s
c
o
p
y
;
  C I
,
 
c
o
n
f
i
d
e
n
c
e
 
i
n
t
e
r
v
a
l
;
  P P V
,
 
p
o
s
i
t
i
v
e
 
p
r
e
d
i
c
t
i
v
e
 
v
a
l
u
e
;
  N P V
,
 
n
e
g
a
t
i
v
e
p
r
e
d
i
c
t
i
v
e
 
v
a
l
u
e
;
  H G D / E C
,
 
h
i
g
h
-
g
r
a
d
e
 
d
y
s
p
l
a
s
i
a
/
e
a
r
l
y
 
c
a
r
c
i
n
o
m
a
.
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e
n
s
i
t
i
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i
t
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,
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p
e
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i
f
i
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i
t
y
,
 
P
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,
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n
d
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V
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l
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e
d
 
f
o
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h
e
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e
t
e
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t
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o
n
 
o
f
 
l
o
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a
t
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o
n
s
 
w
i
t
h
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D
/
E
C
.
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